Investigating how inflammasomes affect melanoma progression
Official title: Role of NLRs in Melanoma
Funded at VA Eastern Colorado Health Care System · NIH-11047189 · Data updated 2026-11-12
This study is looking at how a specific protein called NLRP3 might affect the growth of melanoma, a type of skin cancer, by examining genetic information from patients to see how changes in this protein could influence tumor growth and treatment resistance, which could help find new ways to tackle the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Eastern Colorado Health Care System NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | April 1, 2025 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| NIH project number | 1I01BX006598-01A1 |
| Project ID | NIH-11047189 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with melanoma, particularly those with advanced disease or treatment-resistant tumors.
✕Less likely to help
Patients with non-melanoma skin cancers or those without any genetic mutations in the NLRP3 gene may not benefit from this research.
What this research studies
This research focuses on understanding the role of inflammasomes, specifically the NLRP3 protein, in the progression of melanoma, a type of skin cancer. By analyzing genetic data from melanoma patients, the researchers aim to uncover how mutations in the NLRP3 gene may contribute to tumor growth and resistance to treatment. The study will explore the molecular mechanisms behind these mutations and their impact on inflammation within tumors. This could lead to new insights into how inflammation drives cancer and potential new therapeutic targets.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for melanoma by targeting the inflammasome pathways involved in tumor progression.
How similar studies have gone: While the role of inflammasomes in cancer is an emerging field, previous studies have shown promising results in understanding their impact on tumor biology, suggesting that this approach could yield valuable insights.
Where this research is happening
-
VA Eastern Colorado Health Care System
Aurora, United States Active
Researchers
- Principal investigator: Fujita, Mayumi — VA Eastern Colorado Health Care System
- Study coordinator: Fujita, Mayumi
Related research
Other NIH-funded projects on the same topics.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
-
PLK4 as a potential drug target in melanoma
Researchers are exploring whether blocking PLK4 could be a new way to treat melanoma and how PLK4 works with other melanoma-driving pathways.
-
A new lentivector to deliver multiple TCRs for melanoma cell therapy
A new gene-delivery approach aims to boost T cell receptors inside patients’ own cells to treat advanced melanoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.